Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 977
countries
28
conditions
2 105

16 trials match your criteria

Bipolar I disorder+1

Recruiting

A study testing xanomeline tartrate and trospium chloride added to current treatment for adults with bipolar I disorder experiencing mania

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trospium Chloride

Dementia Alzheimer's type

Recruiting

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Dementia Alzheimer's type

Recruiting

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Trospium Chloride

Schizophrenia+1

Recruiting

Long‑Term Safety and Tolerability of KarXT in Adolescents with Schizophrenia and of KarXT + KarX‑EC in Children and Adolescents with Autism‑Related Irritability

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride

Schizophrenia

Recruiting

A study to evaluate the efficacy and safety of trospium chloride and xanomeline tartrate for the treatment of schizophrenia in adolescents aged 13 to 17 years

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Dementia Alzheimer's type

Recruiting

Study of xanomeline tartrate and trospium chloride combination for treating agitation in Alzheimer's disease patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Bipolar I disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) for treating manic episodes in adults with bipolar I disorder

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Trospium Chloride

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.